DV
Dividend Vision

SYRE — Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. (SYRE)

Total return is -57.6% over the past 10.4 years, 406.8 points behind SPY at 349.2%. Its deepest 1-year drawdown was 14.8%.

Spyre Therapeutics is a clinical-stage biotechnology company developing monoclonal antibody treatments for inflammatory bowel disease and rheumatic diseases, with candidates including SPY001 (in phase-2 for ulcerative colitis and Crohn's disease), SPY002 and SPY072 (anti-TL1A antibodies), and SPY003 (targeting IL-23), along with several combination therapies in development. As an early-stage biotech company, it does not currently distribute dividends. This security appeals primarily to investors with high risk tolerance seeking exposure to clinical-stage therapeutic development, rather than those focused on income generation.

SYRE key facts

Asset type
Stock
Asset class
Equity
Inception date
04/07/2016
Distribution frequency
None
Last close
$103.63
Market cap
$9,137,446,912
Average volume
559500.0
Beta
3.026
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.92